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ABSTRACT
OBJECTIVE: To analyze the free access to medicines for the treatment of chronic diseases 
in the Brazilian population, according to demographic and socioeconomic factors. We also 
analyzed the most used pharmacological groups, according to funding source: free-of-charge 
or out-of-pocket paid.
METHODS: Analysis of data from the Pesquisa Nacional sobre Acesso, Utilização e Promoção 
do Uso Racional de Medicamentos (PNAUM – National Survey on Access, Use and Promotion of 
Rational Use of Medicines), a population-based household survey, of cross-sectional design, based 
on probabilistic sample of the Brazilian population. We analyzed as outcome the prevalence 
of free access ( free-of-charge) to all medicines for treatment of the reported chronic diseases, 
in the last 30 days. We studied the following independent variables: sex, age group, education 
in complete years of school, economic class, health plan, and geographical region of residence. 
We estimated the prevalences and 95% confidence intervals (95%CI) and applied the Pearson’s 
Chi-squared test to assess the differences between the groups, considering a 5% significance level. 
RESULTS: About half of adults and older adults who have had full access to the treatment 
of chronic diseases in Brazil obtained all needed medicines for free (47.5%; 95%CI 45.1–50.0). 
The prevalences of free access were higher among men (51.4%; 95%CI 48.1–54.8), age group of 
40-59 years (51.1%; 95%CI 48.1–54.2), and in the poorest social classes (53.9%; 95%CI 50.2–57.7). 
The majority of medicines that act on the cardiovascular system, such as diuretics (C03) (78.0%; 
95%CI 75.2–80.5), beta-blockers (C07) (62.7%; 95%CI 59.4–65.8), and the agents that work in the 
renin-angiotensin system (C09) (73.4%; 95%CI 70.8–75.8), were obtained for free. Medicines that 
act on the respiratory system, such as agents against obstructive airway diseases (R03) (60.0%; 
95%CI 52.7–66.9) were mostly paid with own resources.
CONCLUSIONS: Free access to medicines for treatment of chronic diseases occurs to a 
considerable portion of the Brazilian population, especially for the poorest ones, indicating 
decreased socioeconomic inequalities, but with differences between regions and between some 
classes of medicines.
DESCRIPTORS: Medicines. Equity in Access. Chronic Disease. National Drug Policy. Health Surveys. 
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INTRODUCTION
Access to medicines is a duty of the Brazilian State, which incorporated, among its principles 
and constitutional guidelines, the guarantee of comprehensive therapeutic care, including 
pharmaceutical services within the Brazilian Unified Health System (SUS). This access occurs 
by the availability of medicines in health-care networks, their geographical accessibility and 
acceptability, promoting the rational use of the products3.
Different strategies have been developed in Brazil to implement the guidelines of 
the National Drug Policy and National Pharmaceutical Services Policy. Among the 
initiatives, we highlight the structuring of pharmaceutical services, the advances of 
regulatory frameworks concerning access to medicines in SUS, the improvement of the 
organization of public pharmaceutical services funding, and the expansion of federal 
resources, among others17. 
The public spending with medicines is growing and is the second largest item of the 
health-care systems total expenditure, surpassed only by hospital care13. Between 2003 
and 2014, the budget of the Brazilian Ministry of Health for pharmaceutical services 
started from 1.9 billion to 12.4 billion Brazilian Reals, with an investment exceeding 
80 billion in the area at the time17. Nevertheless, medicines also represent an important 
item of households health spending, particularly for low-income families and, despite 
the reduction of expenditure with medicines on their income observed in some studies, 
this is still the main component of health spending6,9.
Brazil lives a singular transition, manifested in the coexistence of infectious and parasitic 
diseases, reproductive health problems, external causes, and chronic diseases13, and this 
epidemiological profile requires growing medicine consumption by the population.
Chronic non-communicable diseases are considered one of the most challenging 
problems of world public health24. They are the main causes of death in the world, 
accounting for 68.0% of deaths in 2012. Approximately 75.0% of deaths from these 
diseases occur in low and middle-income countries, and 40.0% are considered premature 
deaths (before 70 years)26. In Brazil, chronic non-communicable diseases have become 
the top priority of public health policies22, since they affect, more intensely, the most 
vulnerable segments of the Country, with the lowest income and schooling2. 
The access to medicines and the guarantee of adequate pharmacological treatment promote 
more effective control of chronic non-communicable diseases, which enables the reduction 
of morbidity and mortality and improves users’ health and quality of life10.
However, epidemiological studies regarding access to free medicines in the Country are still 
scarce. Moreover, national studies use different methods, diverse target population and local 
coverage, which makes difficult comparative analysis of their results and to evaluate the 
impacts of recent pharmaceutical public interventions in the Country1,19,21,a.
This study aimed to analyze the free access to pharmacological treatment for chronic diseases 
in the Brazilian population, according to demographic and socioeconomic factors. We also 
analyzed the most used pharmacological groups, according to source of funding: free or 
paid with own resources.
METHODS
The data analyzed in this study came from the National Survey on Access, Use and 
Promotion of Rational Use of Medicines (PNAUM), a population-based household survey, 
of cross-sectional design, based on probabilistic sample of the Brazilian population. Data 
collection was carried out between September 2013 and February 2014. The population under 
study was of individuals of all ages living in private permanent homes in the urban area of 
a Costa KS. Acesso e uso de 
medicamentos: inquéritos 
de saúde como estratégia de 
avaliação [these]. Campinas (SP): 
Faculdade de Ciências Médicas 
da Universidade Estadual de 
Campinas; 2014.
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the Brazilian territory. We conducted face-to-face interviews in households with application 
of questionnaires, and data were collected in electronic devices.
The instruments used were developed by a group of researchers from Brazilian universities, 
experts in the field, and standardized and tested before being implemented. The sampling 
process was complex and resulted in representative sample of Brazil and its five geographical 
regions, stratified by sex and age groups. Details about the sampling and logistics of data 
collection can be found in the methodological article of PNAUM16.
The analyses of this paper were carried out with two approaches using two databases with 
different denominators. One database refers to the sample of adult population aged 20 years 
or more who reported some chronic disease with more than six months duration in the 
period prior to the interview. The research on access to medicines included all interviewers 
who reported medical indication of medicines for the reported chronic non-communicable 
diseases (n = 12,725), from the question: “In the last 30 days, were you without some of 
these medicines for a while?” Those who reported not being without any of the medicines 
prescribed by the doctor were considered with full access to treatment (n = 10,782). For 
each reported medicine for treatment of chronic diseases, we asked if the product has been 
obtained for free or paid of out-of-pocket.
We analyzed the outcome of prevalence of free access (without pay) to all medicines for 
treatment of the reported chronic diseases, in the last 30 days.
We investigated the following independent variables: sex ( female; male); age group (20-39; 
40-59; 60 or more); education in complete years of schooling (0-8; 9-11; 12 or more); ABEP 
economic classification (http://www.abep.org/) (A/B; C; D/E); health plan (yes; no), and 
geographical region of residence (North; Northeast; Southeast; South; Midwest). We estimated 
the prevalences and 95% confidence intervals (95%CI) and applied the Pearson’s Chi-squared 
test to assess the statistical significance of differences between the groups, considering a 
5% significance level.
The other database is composed of medicines reported by the population aged 20 years or 
more for the treatment of chronic diseases (n = 30,256). For the analysis, the medicines were 
stratified by funding source ( free or paid of out-of-pocket), and classified according to levels 
1 and 2 of the ATC (Anatomical Therapeutic Chemical [ATC] classification system)25, and 
by presence in the Relação Nacional de Medicamentos Essenciais (RENAME – National List 
of Essential Medicines) in force at the time of data collection.
All analyses were performed with the statistical package SPSS 18.0, using the set of CSPLAN 
commands suitable for the analysis of complex samples and ensuring the necessary weight 
to the sample size. 
This study was submitted and approved by the National Commission of Ethics in Research 
(Opinion 398,131, September 16, 2013). All participants (or responsible ones, in the case of 
people unable to answer their own questionnaire) signed an informed consent form.
RESULTS
The majority of people aged 20 years or more who reported medical indication and use of 
medicines to treat chronic diseases (94.3%; 95%CI 93.4–95.1) obtained all the medicines they 
needed in the last 30 days; a small proportion of them (5.1%; 95%CI 4.4–6.0) obtained some 
of the medicines they needed, and only 0.5% (95%CI 0.4–0.7) failed to obtain any medicine 
for their treatment in the past month (Figure 1).
Among those who got full access to treatment, about half of them got all medicines for free 
(47.5%; 95%CI 45.1–50.0), a small part got some free medicine (20.2%; 95%CI 19.0–21.4), 
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and 1/3 (32.3%; 95%CI 30.1–34.6) paid of out-of-pocket for all medicines to treat chronic 
diseases (Figure 1).
Regarding socioeconomic and demographic characteristics, men and individuals aged 
40-59 years showed higher prevalence of free access to all medicines. As for education, the 
prevalence of free access was similar among individuals (Table 1). Regarding economic 
class, the poorest (classes D/E) had greater access to all free medicines to treat the reported 
chronic diseases, as well as those who did not have health plan in relation to who had a plan 
or private insurance (Table 1).
Concerning geographical regions of the country, people living in the North and Southeast 
had higher prevalence of free access to all medicines; the Northeast region presented the 
lowest prevalence (Table 1).
Among adults and older adults who reported full access to treatment, more than half 
reported more than one chronic disease at the time of the interview: 27.1% (95%CI 
25.8–28.4) reported having two chronic diseases and 27.4% (95%CI 25.7–29.2), three or 
more (data not presented). Stratifying free access by the number of reported diseases: 
those with greater number of diseases have had lower prevalence of free access to all 
medicines (35.5%; 95%CI 32.5–38.6) than those who reported one disease (55.5%; 95%CI 
52.4–58.6) (Figure 2). 
Analyzing the pharmacological groups of medicines referred for treatment of chronic diseases, 
we verified that the vast majority is included in the existing RENAME, and, of these, a large 
part was obtained for free (69.0%; 95%CI 66.9–71.0) (Figure 3).
Stratifying the more frequent pharmacological groups for treatment of chronic 
diseases, most medicines that act on the cardiovascular system, such as diuretics 
(C03) (78.0%; 95%CI 75.2–80.5), beta-blockers (C07) (62.7%; 95%CI 59.4–65.8), and 
agents that work in the renin-angiotensin system (C09) (73.4%; 95%CI 70.8–75.8), were 
obtained for free. On the other hand, medicines that act on the respiratory system, 
such as agents against obstructive airway diseases (R03) (60.0%; 95%CI 52.7–66.9), 
were mostly paid of out-of-pocket (Table 2).
94.3%
5.1%
0.5%
47.5%
20.2%
32.3%
Full access Partial access No access
None is free
Some are free
All of them are free
* Percentages weighted by sample weights and post-stratification according to age and sex.
Figure 1. Prevalence of access to treatment of chronic diseases in Brazil and prevalence of free access, 
among those who reported full access to pharmacological treatment.* PNAUM, Brazil, 2014.
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Table 1. Prevalence of free access to all medicines for adults and older adults who have had full access to the 
treatment of chronic diseases, according to socioeconomic and demographic variables. PNAUM, Brazil, 2014.
Variable
Prevalence of free access to all medicines
%a 95%CI Pb
Demographic Characteristics
Sex < 0.001
Male 51.4 48.1–54.8
Female 45.3 42.9–47.8
Age (years) 0.001
20-39 41.2 35.9–46.8
40-59 51.1 48.1–54.2
≥ 60 46.0 43.0–49.0
Socioeconomic characteristics
Education (years of schooling) 0.933
0-8 47.5 44.6–50.6
9-11 47.0 43.7–50.4
≥ 12 47.9 43.6–52.2
Economic classification (ABEP)c < 0.001
A/B 35.8 32.6–39.2
C 50.5 47.7–53.3
D/E 53.9 50.2–57.7
Region of the country 0.074
North 53.0 47.0–58.9
Northeast 43.4 40.1–46.7
Southeast 49.0 44.8–53.3
South 47.8 44.0–51.6
Midwest 44.8 41.1–48.5
Has health plan < 0.001
Yes 27.6 24.9–30.5
No 55.7 53.1–58.1
Total 47.5 45.1–50.0
a Percentages weighted by sample weights and post-stratification according to age and sex. 
b Pearson’s Chi-squared test.
c Associação Brasileira das Empresas Brasileiras (ABEP). Critério de classificação econômica Brasil. São Paulo: 
ABEP; 2013. Available from: http://www.abep.org
1 chronic disease2 chronic diseases3 or more chronic diseases
0
10.0
20.0
30.0
40.0
50.0
60.0
70.0
80.0
90.0
100
35.5
46.7
55.5
(%
)
* Percentages weighted by sample weights and post-stratification according to age and sex. 
Figure 2. Prevalence of free access to all medicines according to the number of chronic diseases reported 
by Brazilians adults and older adults who reported full access to treatment for chronic diseases.* 
PNAUM, Brazil, 2014. 
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DISCUSSION
This study identified that about half of adults and older adults who have had full access 
to the treatment of chronic diseases in Brazil got all medicines they needed for free. The 
prevalence of free access occurs differently between men and women and between Brazil’s 
regions, being higher in the North and Southeast regions and in poorer social classes.
Table 2. Groups of the ATCa classification more used by adults and older adults for the treatment of 
chronic diseases according to funding source of the medicines (free of charge or paid of out-of-pocket). 
PNAUM, Brazil, 2014. 
ATC classification levels 1 and 2
Funding source of the medicine
% paidb 95%CI % freeb 95%CI
A: Digestive apparatus and metabolism
A10 Medicine used for diabetes 21.4 18.7–24.4 78.6 75.6–81.3
C: Cardiovascular system
C01 Cardiac therapy 56.2 49.5–62.6 43.8 37.4–50.5
C02 Antihypertensives 50.4 41.7–59.1 49.6 40.9–58.3
C03 Diuretics 22.0 19.5–24.8 78.0 75.2–80.5
C07 Beta-blockers 37.3 34.2–40.6 62.7 59.4–65.8
C0 Calcium channel blockers 41.4 36.3–46.7 58.6 53.3–63.7
C09 Agents acting on the renin-angiotensin system 26.6 24.2–29.2 73.4 70.8–75.8
C10 Lipids modifier agents 44.6 40.7–48.6 55.4 51.4–59.3
N: Nervous system
N06 Psychoanaleptics 41.5 37.5–45.6 58.5 54.4–62.5
N03 Antiepileptics 41.2 36.0–46.7 58.8 53.3–64.0
N05 Psycholeptics 45.3 39.1–51.6 54.7 48.4–60.9
N04 Antiparkinson 26.4 17.2–38.2 73.6 61.8–82.8
R: Respiratory system
R03 Agents against airway obstructive diseases 60.0 52.7–66.9 40.0 33.1–47.3
R06 Antihistamines for systemic use 56.6 43.3–69.1 43.4 30.9–56.7
ATC: Anatomical Therapeutic Chemical classification system
a ATC levels 1 and 2.
b Percentages adjusted by sample weights and post-stratification according to age and sex. 
Medicines used for the treatment of chronic diseases reported 
by respondents aged 20 or more years old
77.0%a
are on RENAMEb
69.0%a
of those listed in RENAME were 
obtained for free
31.0%a 
of those listed in RENAME were paid 
of out-of-pocket
a Percentage adjusted by sample weights and post-stratification according to age and sex.
b RENAME - Relação de Medicamentos Essenciais 2013, 8ª Edição, 2014. Available from: http://www.youblisher.
com/p/941590-Rename/ 
Figure 3. Classification of the medicines reported for treatment of chronic diseases of adults and older 
adults in Brazil according to RENAMEb and funding source (free or paid of out-of-pocket). PNAUM, 
Brazil, 2014. 
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This is the first population-based study that investigates the access to medicines with 
representative sample of the population living in the urban area of the five regions of Brazil, 
allowing the generalization of results for the Brazilian population. As methodological strategy, 
we analyzed the free access to the treatment of chronic diseases in those who reported 
full access to treatment, analyzing the socioeconomic and demographic differences in the 
Country, as well as the source of funding for pharmacological groups most used by the 
Brazilian population.
Considering obtaining from all sources of funding, the prevalence of full access to the 
treatment of chronic diseases was high, similar to that found in other studies carried out 
in Brazil, despite the limitation of comparisons due to differences of recall periods and 
study approaches4,8,19,20. The access level found matched the results of the World Health 
Survey, conducted in 2002 and 2003 in 70 countries. In this investigation, 72.0% to 85.0% of 
respondents reported obtaining all or most of the medicines for conditions treatable in the 
last 12 months23. 
The prevalence found here confirms the results of the National Household Sample Survey 
(PNAD) conducted in 2008 in Brazil by the Brazilian Institute of Geography and Statistics 
(IBGE). PNAD assessed the population that had medicines prescribed in SUS, of which 45.3% 
obtained them in the public system7. We need caution when comparing these data, given 
that PNAD analyzed only the access of prescriptions from SUS, and this study examined all 
sources; however, both results indicate that about half of the Brazilian population gets free 
access to treatment since 2008.
Considering more prevalent chronic diseases, as hypertension and diabetes, recent 
publications point out the role of SUS as an important provider of medicines. The 
Surveillance System of Risk and Protection Factors for Chronic Diseases by Telephone 
Survey (VIGITEL) noted that, in the analyzed period (2011-2013), about 60.0% of 
medicines to control hypertension and more than 70.0% of diabetes medicines were 
obtained for free by adults (≥ 18 years), whether by the primary healthcare unit or 
by the Farmácia Popular (Popular Pharmacy Program)18. The analysis of the National 
Survey on Health (PNS 2013) showed that the vast majority of patients using medicines 
for hypertension has a single source for obtaining them, with about half of the supply 
of medicines by SUS (whether by public health system’s pharmacies or by the Popular 
Pharmacy Program), one third exclusively by private pharmacies, and small participation 
by private health plans15.
Free access to all medicines to treat chronic diseases reported in the last month differed 
according to socioeconomic and demographic characteristics. The poorest had greater free 
access to all medicines to treat chronic diseases, strengthening the hypothesis that SUS is 
promoting equity in access to medicines19. This finding is important, considering the inverse 
association between socioeconomic position and under-utilization of medicines, and that, 
in these population sectors, the public health system is often the only alternative to enable 
the needed therapy6,7,14. 
Regarding the differences in the five regions of the Country, the Northeast region showed the 
lowest prevalence of free access to all medicines, which has been observed in prior studies7,21. 
Considering that, in the Northeast region, 78.0% of cities have low Human Development 
Index (HDI) of Incomeb and that the income expenditure on purchasing medicines can be 
almost three times higher among the poorest (7.3%), when compared to the richest (2.7%)6, 
these results may indicate that the population of this region is more vulnerable to treatment 
discontinuation because of inability to pay for treatment with medicines for chronic diseases11.
Chronic non-communicable diseases are the main sources of disease burden in Brazil, 
and important policies to their prevention and control have been implemented, 
including the expansion of access to medicines policies, such as the free treatment for 
hypertension, diabetes, and asthma by the Popular Pharmacy Program22. In this study, 
b Programa Nacional das 
Nações Unidas para o 
desenvolvimento (PNUD). Atlas 
do desenvolvimento humano 
no Brasil 2013: IDHM Renda. 
Brasília (DF); 2013 [cited 2014 
Sept 20]. Available from: http://
www.pnud.org.br/arquivos/ 
idhm-renda.pdf
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we highlight the importance of these policies on access to medicines in the Country. 
However, free access to medicines in Brazil is lower for individuals with higher number 
of chronic diseases, indicating that full access to treatment is still a gap to be addressed 
by the managers of the health-care network.
To implement free access for the population, the deficiencies found in studies in recent years 
relating to the management of pharmaceutical services5,11,14, such as the low availability of 
medicines in public health units, must be focus of interventions of SUS managers, toward 
the promotion of free access to medicines in the Country. Moreover, we stress that, in this 
study, most medicines obtained for free by the Brazilian population were included in the 
existing RENAME, a guiding instrument for the selection and care of diseases and harms 
within the SUS, showing that the targeting of this use of medicines rationalization strategy 
complies with the needs of the population.
Cardiovascular diseases, despite their reduction, are the leading cause of death in Brazil22. 
In this study, most medicines used for the treatment of these diseases by the Brazilian 
population were obtained for free, a number higher than that of a study carried out 
previously in two Brazilian regions21. This result may suggest that the expansion of access 
strategies for pharmaceutical services reorganization and funding implemented in the 
Country in recent years have been effective in increasing free access to these medicines 
for the Brazilian population. However, the high out-of-pocket expenditure on medicines 
for respiratory system related conditions show gaps on access to this group of medicines, 
which are used for chronic diseases such as asthma and involve access to health services 
and diagnostics. 
We can conclude that free access to medicines for treatment of chronic non-communicable 
diseases has been effective to a considerable portion of the Brazilian population, especially 
for the poorest ones, indicating decreased socioeconomic inequalities, but with differences 
between regions and between classes of medicines. 
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